Global Alzheimer's Disease Drug 麻豆原创 Growth 2025-2031

Publication ID:

LPI07254798

Publication Date:

July 4, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Alzheimer's Disease Drug market size is predicted to grow from US$ 3695 million in 2025 to US$ 4053 million in 2031; it is expected to grow at a CAGR of 1.6% from 2025 to 2031.
Alzheimer"s disease (AD), also referred to simply as Alzheimer"s, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.
The major players in global Alzheimer鈥檚 Disease Drug market include Allergan, Eisai, Novartis, Daiichi Sankyo, Merz Pharma, Pfizer, Johnson & Johnson, Lundbeck, etc. The top 3 players hold over 60% of global shares. Europe and North America are main markets, they occupy over 70% of the global market. Memantine and Donepezil are the main types, with a share about 70%. Early to Moderate Stages is the key application, which covers over 55% shares.
The 鈥淎lzheimer's Disease Drug Industry Forecast鈥� looks at past sales and reviews total world Alzheimer's Disease Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Alzheimer's Disease Drug sales for 2025 through 2031. With Alzheimer's Disease Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Alzheimer's Disease Drug industry.
This Insight Report provides a comprehensive analysis of the global Alzheimer's Disease Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Alzheimer's Disease Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Alzheimer's Disease Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Alzheimer's Disease Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Alzheimer's Disease Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Alzheimer's Disease Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Donepezil
Memantine
Rivastigmine
Others
Segmentation by Application:
Early to Moderate Stages
Moderate to Severe Stages
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Allergan
Eisai
Novartis
Daiichi Sankyo
Merz Pharma
Pfizer
Johnson & Johnson
Lundbeck
Key Questions Addressed in this Report
What is the 10-year outlook for the global Alzheimer's Disease Drug market?
What factors are driving Alzheimer's Disease Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Alzheimer's Disease Drug market opportunities vary by end market size?
How does Alzheimer's Disease Drug break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Alzheimer's Disease Drug Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Alzheimer's Disease Drug by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Alzheimer's Disease Drug by Country/Region, 2020, 2024 & 2031
2.2 Alzheimer's Disease Drug Segment by Type
2.2.1 Donepezil
2.2.2 Memantine
2.2.3 Rivastigmine
2.2.4 Others
2.3 Alzheimer's Disease Drug Sales by Type
2.3.1 Global Alzheimer's Disease Drug Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Alzheimer's Disease Drug Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Alzheimer's Disease Drug Sale Price by Type (2020-2025)
2.4 Alzheimer's Disease Drug Segment by Application
2.4.1 Early to Moderate Stages
2.4.2 Moderate to Severe Stages
2.5 Alzheimer's Disease Drug Sales by Application
2.5.1 Global Alzheimer's Disease Drug Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Alzheimer's Disease Drug Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Alzheimer's Disease Drug Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Alzheimer's Disease Drug Breakdown Data by Company
3.1.1 Global Alzheimer's Disease Drug Annual Sales by Company (2020-2025)
3.1.2 Global Alzheimer's Disease Drug Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Alzheimer's Disease Drug Annual Revenue by Company (2020-2025)
3.2.1 Global Alzheimer's Disease Drug Revenue by Company (2020-2025)
3.2.2 Global Alzheimer's Disease Drug Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Alzheimer's Disease Drug Sale Price by Company
3.4 Key Manufacturers Alzheimer's Disease Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Alzheimer's Disease Drug Product Location Distribution
3.4.2 Players Alzheimer's Disease Drug Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Alzheimer's Disease Drug by Geographic Region
4.1 World Historic Alzheimer's Disease Drug 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Alzheimer's Disease Drug Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Alzheimer's Disease Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Alzheimer's Disease Drug 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Alzheimer's Disease Drug Annual Sales by Country/Region (2020-2025)
4.2.2 Global Alzheimer's Disease Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Alzheimer's Disease Drug Sales Growth
4.4 APAC Alzheimer's Disease Drug Sales Growth
4.5 Europe Alzheimer's Disease Drug Sales Growth
4.6 Middle East & Africa Alzheimer's Disease Drug Sales Growth
5 Americas
5.1 Americas Alzheimer's Disease Drug Sales by Country
5.1.1 Americas Alzheimer's Disease Drug Sales by Country (2020-2025)
5.1.2 Americas Alzheimer's Disease Drug Revenue by Country (2020-2025)
5.2 Americas Alzheimer's Disease Drug Sales by Type (2020-2025)
5.3 Americas Alzheimer's Disease Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Alzheimer's Disease Drug Sales by Region
6.1.1 APAC Alzheimer's Disease Drug Sales by Region (2020-2025)
6.1.2 APAC Alzheimer's Disease Drug Revenue by Region (2020-2025)
6.2 APAC Alzheimer's Disease Drug Sales by Type (2020-2025)
6.3 APAC Alzheimer's Disease Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Alzheimer's Disease Drug by Country
7.1.1 Europe Alzheimer's Disease Drug Sales by Country (2020-2025)
7.1.2 Europe Alzheimer's Disease Drug Revenue by Country (2020-2025)
7.2 Europe Alzheimer's Disease Drug Sales by Type (2020-2025)
7.3 Europe Alzheimer's Disease Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Alzheimer's Disease Drug by Country
8.1.1 Middle East & Africa Alzheimer's Disease Drug Sales by Country (2020-2025)
8.1.2 Middle East & Africa Alzheimer's Disease Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Alzheimer's Disease Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Alzheimer's Disease Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Alzheimer's Disease Drug
10.3 Manufacturing Process Analysis of Alzheimer's Disease Drug
10.4 Industry Chain Structure of Alzheimer's Disease Drug
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Alzheimer's Disease Drug Distributors
11.3 Alzheimer's Disease Drug Customer
12 World Forecast Review for Alzheimer's Disease Drug by Geographic Region
12.1 Global Alzheimer's Disease Drug 麻豆原创 Size Forecast by Region
12.1.1 Global Alzheimer's Disease Drug Forecast by Region (2026-2031)
12.1.2 Global Alzheimer's Disease Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Alzheimer's Disease Drug Forecast by Type (2026-2031)
12.7 Global Alzheimer's Disease Drug Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Allergan
13.1.1 Allergan Company Information
13.1.2 Allergan Alzheimer's Disease Drug Product Portfolios and Specifications
13.1.3 Allergan Alzheimer's Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Allergan Main Business Overview
13.1.5 Allergan Latest Developments
13.2 Eisai
13.2.1 Eisai Company Information
13.2.2 Eisai Alzheimer's Disease Drug Product Portfolios and Specifications
13.2.3 Eisai Alzheimer's Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Eisai Main Business Overview
13.2.5 Eisai Latest Developments
13.3 Novartis
13.3.1 Novartis Company Information
13.3.2 Novartis Alzheimer's Disease Drug Product Portfolios and Specifications
13.3.3 Novartis Alzheimer's Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Novartis Main Business Overview
13.3.5 Novartis Latest Developments
13.4 Daiichi Sankyo
13.4.1 Daiichi Sankyo Company Information
13.4.2 Daiichi Sankyo Alzheimer's Disease Drug Product Portfolios and Specifications
13.4.3 Daiichi Sankyo Alzheimer's Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Daiichi Sankyo Main Business Overview
13.4.5 Daiichi Sankyo Latest Developments
13.5 Merz Pharma
13.5.1 Merz Pharma Company Information
13.5.2 Merz Pharma Alzheimer's Disease Drug Product Portfolios and Specifications
13.5.3 Merz Pharma Alzheimer's Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Merz Pharma Main Business Overview
13.5.5 Merz Pharma Latest Developments
13.6 Pfizer
13.6.1 Pfizer Company Information
13.6.2 Pfizer Alzheimer's Disease Drug Product Portfolios and Specifications
13.6.3 Pfizer Alzheimer's Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Pfizer Main Business Overview
13.6.5 Pfizer Latest Developments
13.7 Johnson & Johnson
13.7.1 Johnson & Johnson Company Information
13.7.2 Johnson & Johnson Alzheimer's Disease Drug Product Portfolios and Specifications
13.7.3 Johnson & Johnson Alzheimer's Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Johnson & Johnson Main Business Overview
13.7.5 Johnson & Johnson Latest Developments
13.8 Lundbeck
13.8.1 Lundbeck Company Information
13.8.2 Lundbeck Alzheimer's Disease Drug Product Portfolios and Specifications
13.8.3 Lundbeck Alzheimer's Disease Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Lundbeck Main Business Overview
13.8.5 Lundbeck Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.